公开(公告)号：US12077488B2

公开(公告)日：2024-09-03

申请号：US17316034

申请日：2021-05-10

Applicant: Intervet Inc.

Inventor： Michael Berger ,  Thorsten Meyer ,  Joachim Ullrich ,  Ralf Warrass

IPC: A61K31/165 ,  A61P11/00 ,  A61P31/04 ,  C07C259/06 ,  C07C317/50 ,  C07C323/60 ,  C07D205/04 ,  C07D207/14 ,  C07D213/56 ,  C07D217/18 ,  C07D233/64 ,  C07D235/14 ,  C07D259/00 ,  C07D267/10 ,  C07D277/28 ,  C07D295/00 ,  C07D295/155 ,  C07D307/52 ,  C07D307/56 ,  C07D317/50 ,  C07D333/20 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12

CPC classification number: C07C259/06 ,  A61P11/00 ,  A61P31/04 ,  C07C317/50 ,  C07C323/60 ,  C07D213/56 ,  C07D217/18 ,  C07D235/14 ,  C07D267/10 ,  C07D277/28 ,  C07D295/155 ,  C07D307/52 ,  C07D333/20 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2601/16

Abstract: The present invention discloses compounds that are useful in the treatment of respiratory diseases of animals, especially Bovine or Swine Respiratory disease (BRD and SRD).

公开(公告)号：US20240067598A1

公开(公告)日：2024-02-29

申请号：US18223855

申请日：2023-07-19

Applicant: ReNAgade Therapeutics Management Inc.

Inventor： Stephen Scully ,  Muthusamy Jayaraman ,  Ganapathy Subramanian Sankaran

IPC: C07C229/12 ,  A61K9/51 ,  A61K48/00 ,  C07D233/61 ,  C07J41/00 ,  C07D277/56 ,  C07D277/28

CPC classification number: C07C229/12 ,  A61K9/5123 ,  A61K48/0033 ,  C07D233/61 ,  C07J41/0088 ,  C07D277/56 ,  C07D277/28 ,  C07C2603/74 ,  C07C2602/38 ,  C07C2602/44 ,  C07C2602/42

Abstract: The present disclosure details various lipids, compositions, and/or methods of optimized systems and delivery vehicles for the delivery of nucleic acid sequences, polypeptides or peptides for use in vaccinating against infectious agents.

公开(公告)号：US11897852B2

公开(公告)日：2024-02-13

申请号：US17172543

申请日：2021-02-10

Applicant: The University of Toledo

Inventor： Bruce E. Heck ,  Dong Hyun Kim ,  Paul W. Erhardt ,  Brian Kress

IPC: A61K31/426 ,  A61P19/02 ,  C07D277/24 ,  A61K31/5575 ,  A61K45/06 ,  C07D277/28 ,  C07D277/22

CPC classification number: C07D277/24 ,  A61K31/426 ,  A61K31/5575 ,  A61K45/06 ,  C07D277/22 ,  C07D277/28 ,  A61K31/5575 ,  A61K2300/00 ,  A61K31/426 ,  A61K2300/00

Abstract: Peroxisome proliferator activated receptor (PPAR) compounds, and methods of using the same for treating bone fractures, treating osteoporosis and/or metabolic bone diseases, and inducing osteogenesis and/or chondrogenesis, are disclosed.

公开(公告)号：US20230357139A1

公开(公告)日：2023-11-09

申请号：US18025818

申请日：2021-09-13

Applicant: Artizan Biosciences, Inc.

Inventor： William HOEKSTRA ,  Hyunji RYU ,  Priyanka CHINTHA

IPC: C07C311/29 ,  C07D333/34 ,  C07D213/42 ,  C07D213/71 ,  C07D231/12 ,  C07D401/12 ,  C07D209/08 ,  C07D333/36 ,  C07D409/12 ,  C07D401/08 ,  C07D231/56 ,  C07D413/12 ,  C07D277/28

CPC classification number: C07C311/29 ,  C07D333/34 ,  C07D213/42 ,  C07D213/71 ,  C07D231/12 ,  C07D401/12 ,  C07D209/08 ,  C07D333/36 ,  C07D409/12 ,  C07D401/08 ,  C07D231/56 ,  C07D413/12 ,  C07D277/28

Abstract: Described herein are compounds and compositions for use in treatment or prevention of an inflammatory bowel disease, gastrointestinal cancer, or a systemic bacterial infection in a subject in need thereof. The subject may be colonized by one or more pathogenic bacterial strains such as B. fragilis, E. faecalis, or C. perfringens. In certain aspects, the disclosure provides a method of diminishing the pathogenic effects of these bacterial strains by administering a compound that binds to and/or inhibits one or more toxins produced thereby.

公开(公告)号：US11680073B2

公开(公告)日：2023-06-20

申请号：US17511265

申请日：2021-10-26

Applicant: ADT PHARMACEUTICALS, LLC

Inventor： Michael Boyd ,  Xi Chen

IPC: C07F5/02 ,  C07C235/32 ,  C07D213/40 ,  C07D213/56 ,  C07D231/40 ,  C07D261/08 ,  C07D277/28 ,  C07D307/52 ,  C07D317/12 ,  C07D327/04

CPC classification number: C07F5/025 ,  C07C235/32 ,  C07D213/40 ,  C07D213/56 ,  C07D231/40 ,  C07D261/08 ,  C07D277/28 ,  C07D307/52 ,  C07D317/12 ,  C07D327/04 ,  C07B2200/07

Abstract: Disclosed are compounds for medical uses, for example, compounds of formula Ia,




wherein A1, A2, A3, A4, A5, A6, A7, R6, R7 and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.

公开(公告)号：US20220378750A1

公开(公告)日：2022-12-01

申请号：US17680782

申请日：2022-02-25

Applicant: EYEPOINT PHARMACEUTICALS, INC.

Inventor： Jeffrey Lyle Gray ,  Kande K.D. Amarasinghe ,  Cynthia Monesa Clark ,  Ryan Matthew Nichols ,  Matthew B. Maier

IPC: A61K31/426 ,  C07D277/64 ,  C07D277/28 ,  C07D417/04 ,  A61K31/427 ,  A61K31/428 ,  A61K31/497 ,  C07D277/60 ,  C07D277/30 ,  A61K9/00

Abstract: The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising said human protein tyrosine phosphatase beta (HPTP-β) inhibitors, and to methods for regulating angiogenesis.

公开(公告)号：US11465987B2

公开(公告)日：2022-10-11

申请号：US15270359

申请日：2016-09-20

Applicant: ONCTERNAL THERAPEUTICS, INC. ,  UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION

Inventor： Wei Li ,  Min Xiao ,  James Dalton ,  Sunjoo Ahn ,  Duane D Miller ,  Jin Wang

IPC: C07D403/04 ,  C07D233/64 ,  A61K31/4164 ,  A61K45/06 ,  C07D417/04 ,  C07D263/32 ,  C07D277/24 ,  C07D277/28 ,  C07D277/56 ,  A61K31/4174 ,  A61K31/4178 ,  C07D233/88

Abstract: The present invention relates to novel compounds having anti-cancer activity, methods of making these compounds, and their use for treating cancer and drug-resistant tumors, e.g. melanoma, metastatic melanoma, drug resistant melanoma, prostate cancer and drug resistant prostate cancer.

公开(公告)号：US20220117946A1

公开(公告)日：2022-04-21

申请号：US17096548

申请日：2020-11-12

Applicant: Aerpio Pharmaceuticals, Inc.

Inventor： Jeffrey Lyle Gray ,  Kande K.D. Amarasinghe ,  Cynthia Monesa Clark ,  Ryan Matthew Nichols ,  Matthew B. Maier

IPC: A61K31/426 ,  C07D277/64 ,  C07D277/28 ,  C07D417/04 ,  A61K31/427 ,  A61K31/428 ,  A61K31/497 ,  C07D277/60 ,  C07D277/30 ,  A61K9/00

Abstract: The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising said human protein tyrosine phosphatase beta (HPTP-β) inhibitors, and to methods for regulating angiogenesis.

公开(公告)号：US20220089555A1

公开(公告)日：2022-03-24

申请号：US17424292

申请日：2020-01-21

Applicant: Hangzhou Yirui Pharmaceutical Technology Co., Ltd

Inventor： Xiaolu WANG ,  Yongzhou HU ,  Qing YE ,  Xiuai HU

IPC: C07D295/205 ,  C07D211/74 ,  C07D211/46 ,  C07D295/155 ,  C07D211/54 ,  C07D207/14 ,  C07D211/88 ,  C07D233/36 ,  C07D307/52 ,  C07D277/28 ,  C07D233/64 ,  C07D231/12 ,  C07D213/42 ,  C07D211/52 ,  C07D211/58 ,  C07D241/08 ,  A61P17/06

Abstract: The invention provides an N-benzyl-N-arylsulfonamide derivative, which is an N-benzyl-N-arylsulfonamide compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof. The N-benzyl-N-arylsulfonamide derivative is obtained by condensing a substituted nitrobenzene with 5- or 6-membered nitrogen-containing aliphatic heterocycle (the ring B), reducing the nitro group to an amino group, and subjecting the amino group to reductive amination, sulfonamidation; or by subjecting a substituted nitrobenzene to nitro reduction, reductive amination and sulfonamidation, and condensing the resultant intermediate with 5- or 6-membered nitrogen-containing aliphatic heterocycle (the ring B). It has been experimentally demonstrated that the N-benzyl-N-arylsulfonamide derivative of the invention can specifically bind to Kv1.3 potassium channel and inhibit or decrease its activity, and is useful in the treatment of autoimmune diseases caused by abnormal activation of the Kv1.3 potassium channel in human or animals. The invention further provides a medicament or a pharmaceutical composition comprising the N-benzyl-N-arylsulfonamide derivative.

公开(公告)号：US20210163431A1

公开(公告)日：2021-06-03

申请号：US17172543

申请日：2021-02-10

Applicant: The University of Toledo

Inventor： Bruce E. Heck ,  Dong Hyun Kim ,  Paul W. Erhardt ,  Brian Kress

IPC: C07D277/24 ,  A61K31/426 ,  A61K31/5575 ,  A61K45/06 ,  C07D277/28 ,  C07D277/22

Abstract: Peroxisome proliferator activated receptor (PPAR) compounds, and methods of using the same for treating bone fractures, treating osteoporosis and/or metabolic bone diseases, and inducing osteogenesis and/or chondrogenesis, are disclosed.